Cuvat, France

Laurent Chevalet

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Laurent Chevalet

Introduction

Laurent Chevalet is a notable inventor based in Cuvat, France. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides that target specific interleukins. With a total of three patents to his name, Chevalet's work is paving the way for advancements in medical treatments.

Latest Patents

Chevalet's latest patents focus on polypeptides that bind to IL-17A, IL-17F, and/or IL-17A/F. These patents describe amino acid sequences that are directed against these interleukins, including combinations thereof. The disclosures also cover compounds or constructs, particularly proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. This innovative approach has the potential to lead to new methods of treatment for various conditions.

Career Highlights

Laurent Chevalet is currently associated with Merck Patent GmbH, where he continues to push the boundaries of scientific research and innovation. His work has garnered attention in the biotechnology sector, showcasing his expertise and commitment to advancing medical science.

Collaborations

Chevalet collaborates with esteemed colleagues such as Heidi Rommelaere and Joost Alexander Kolkman. These partnerships enhance the research and development efforts within his field, contributing to the success of their projects.

Conclusion

Laurent Chevalet's contributions to biotechnology through his innovative patents and collaborations highlight his role as a leading inventor in the industry. His work is instrumental in developing new therapeutic approaches that could significantly impact healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…